Aranesp

Manufactured by Amgen

Sourced in United States

Aranesp is a laboratory equipment product that serves as a core function. It is designed to assist with specific tasks within the laboratory environment.

Automatically generated - may contain errors

Lab products found in correlation

Mircera, by Roche (2 mentions) Epogen, by Amgen (1 mentions) Viagra, by Pfizer (1 mentions) Glycerol, by Merck Group (1 mentions) Bromophenol blue, by Merck Group (1 mentions) Immobilon ecl ultra western hrp substrate, by Merck Group (1 mentions) Nupage antioxidant, by Thermo Fisher Scientific (1 mentions) Tris hydroxymethyl aminomethane, by Merck Group (1 mentions) Dl dithiothreitol, by Merck Group (1 mentions) Extra thick blot paper, by Bio-Rad (1 mentions) Streptavidin pod conjugate, by Roche (1 mentions) L name, by Merck Group (1 mentions)

6 protocols using aranesp

Standardized Protocols for Anemia Management

Check if the same lab product or an alternative is used in the 5 most similar protocols

As all clinical parameters, the two primary outcomes, monthly ESA consumption and hemoglobin levels were routinely collected according to standardized clinical protocols and procedures of the NephroCare clinics [30 (link)].
All ESA doses were normalized to IUs (international units). For darbepoetin alfa (Aranesp, Amgen, Thousand Oaks, CA, USA) and methoxy-polyethylene-glycol-epoetin beta (MIRCERA; F. Hoffmann-La Roche Ltd, Basel, Switzerland), the original doses (in μg) were converted to IUs by using the factors 200 and 225, respectively [31 , 32 (link)]. The monthly ESA dose was calculated as the total ESA consumption within a 4-week interval (28 days).

Pedrini L.A., Zawada A.M., Winter A.C., Pham J., Klein G., Wolf M., Feuersenger A., Ruggiero P., Feliciani A., Barbieri C., Gauly A., Canaud B, & Stuard S. (2019). Effects of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients. PLoS ONE, 14(2), e0212795.

+ Open protocol

+ Expand

Anemia-Management Drugs Costs for Hemodialysis Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

A recent report published by CMS on costs of anemia-management drugs for hemodialysis (HD) patients provided mean per HD session doses for the ESA drugs (Epogen^® and Aranesp^® [Amgen Inc., CA, USA]) and IV iron drugs (Venofer^® [American Regent, Inc., NY, USA] and Ferrlecit^®, [Sanofi US, Bridgewater, NJ, USA]).2 Utilization costs of these four drugs were based on RED BOOK costs combined with CMS base rate and actual usage in 2011. Regarding ESAs and CMS base rates, Epogen was used much more frequently than Aranesp, with a calculated PPPY cost of US$12,243. For Aranesp, the calculated PPPY cost was US$1,426. For actual 2011 utilization, the PPPY costs for Epogen and Aranesp were US$9,545 and US$543. For iron, when applying the CMS base rate to RED BOOK costs, Venofer was used more frequently than Ferrlecit, and had a calculated PPPY cost of US$1,057. On the other hand, Ferrlecit usage resulted in a calculated PPPY cost of US$432. Calculated PPPY costs for Venofer and Ferrlecit based on actual 2011 utilization were US$1,148 and US$209, respectively. Table 1 lists the sources of information used for determining utilization costs, and the resulting lower, middle, and upper cost boundaries. We set the upper bound of triangle distributions equal to the mode plus 10%.

Thomas A, & Peterson L.E. (2014). Reduction of costs for anemia-management drugs associated with the use of ferric citrate. International Journal of Nephrology and Renovascular Disease, 7, 191-201.

+ Open protocol

+ Expand

Erythropoietin and Sildenafil Effects in Rats

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human erythropoietin was used in the form of injections (Aranesp, Amgen, Holland). A dose of 1,000 IU/kg was injected intraperitoneally in the rats of group C (low-dose erythropoietin group) and a dose of 3,000 IU/kg was injected intraperitoneally in the rats of group D (high-dose erythropoietin group). Sildenafil in the form of commercially packed tablets (Viagra; Pfizer, Walton Oaks, UK) was also obtained. Each tablet contained 100 mg of sildenafil. The tablets were grinded and dissolved in sterile 0.9% w/v NaCl solution, forming a 20% w/v sildenafil solution. A dose of 0.7 mg/kg was injected intraperitoneally in the rats of group E (sildenafil group). These doses of erythropoietin and sildenafil have been reported by previous studies (16 (link)–22 (link)).

Kostakis I.D., Zavras N., Damaskos C., Sakellariou S., Korkolopoulou P., Misiakos E.P., Tsaparas P., Vaos G, & Karatzas T. (2017). Erythropoietin and sildenafil protect against ischemia/reperfusion injury following testicular torsion in adult rats. Experimental and Therapeutic Medicine, 13(6), 3341-3347.

+ Open protocol

+ Expand

Erythropoietin Effects on Hematocrit

Check if the same lab product or an alternative is used in the 5 most similar protocols

A detailed description of the original study design has been published previously (11 (link)). In brief, in the present sub-study, volunteers were allocated in a single-blinded, randomized, parallel design to either a sedentary and placebo treatment control (C) group (n = 9) or a sedentary and ESA (Darbepoietin–α, Aranesp; Amgen, Thousand Oaks, CA) treatment group (n = 8) for 10 weeks. Once a week, ESA was administered subcutaneously at a dose of 40 µg for the first 3 weeks and 20 µg for the remaining 7 weeks. Hematocrit was measured weekly throughout the study. The first three subjects, however, received treatment twice a week for the first 3 weeks, which led to a greater increase in the hematocrit than expected (50–54%). Hence, the number of injections was reduced to once a week. As per protocol, some subjects were intermittently switched to placebo in order to keep the hematocrit value below 55%. From 1 week before the treatment until the end of the study the subjects were supplemented with 100 mg iron orally/day (Ferrosulfat, Ferro Duretter; GlaxoSmithKline, Brentford, UK).

Risikesan J., Nellemann B., Christensen B., Jørgensen J.O, & Nielsen S. (2020). No effect of 10 weeks erythropoietin treatment on lipid oxidation in healthy men. Endocrine Connections, 9(12), 1148-1155.

+ Open protocol

+ Expand

Western Blot Analysis of Erythropoietin Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols

Reference standards used were as follows: methoxypolyethylen‐glycol‐epoetin beta, MIRCERA (CERA; Roche, Basel Switzerland), darbepoetin alfa, Aranesp (Novel erythropoietin stimulating protein, NESP; Amgen; CA, USA), human EPO‐alpha Fc (EPO‐Fc; ProSpec; Rehovot, Israel), and biological reference protein (BRP—a reference substance for rEPOs; European Directorate for the Quality of Medicines and HealthCare, Strasbourg, France). Methanol was from J.T. Baker (NJ, USA). Bromophenol blue and Immobilon® ECL Ultra Western HRP Substrate were from Merck Millipore Ltd (MA, USA). Sodium N‐lauroylsarcosinate (SAR), sodium dodecyl sulphate (SDS), 3‐(N‐morpholino)‐propane sulfonic acid (MOPS), ethylenediaminetetraacetic acid (EDTA), glycine, glycerol, tris (hydroxymethyl)aminomethane and DL‐dithiothreitol (DTT) were from Sigma‐Aldrich (MO, USA). NuPAGE antioxidant and Gibco phosphate‐buffered saline (PBS) tablets were purchased from Thermo Fisher Scientific (MA, USA). Powdered milk was purchased from Carl Roth (Karlsruhe, Germany). Extra thick blot paper was from Bio‐Rad (CA, USA). Human EPO biotinylated antibody monoclonal mouse IgG2A clone #AE7A5 was from R&D Systems (MN, USA), and Streptavidin‐POD conjugate was from Roche (Basel, Switzerland).

Heiland C.E., Ericsson M., Pohanka A., Ekström L, & Marchand A. (2022). Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti‐doping application. Drug Testing and Analysis, 14(8), 1377-1386.

+ Open protocol

+ Expand

Depo Dose and Treatment Study

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dose study. To detect the appropriate dose of Depo (Aranesp; AMGEN, Thousand Oaks, CA, USA) we randomly divided 60 female adult rats into 6 groups: L-NAME (20 mg/kg/day; Sigma Aldrich, St. Louis, MO, USA) alone, L-NAME + 0.1 µg/kg Depo, L-NAME + 0.25 µg/kg Depo, L-NAME + 0.5 µg/kg Depo, L-NAME + 2.5 µg/kg Depo, and L-NAME + 10 µg/kg Depo. Due to the half-life of Depo, it was injected once every 3 days. According to the survival and blood parameters, 0.25 µg/kg Depo was determined as the highest dose that did not change the blood parameters and was used as the treatment dose throughout the rest of the study (Table 1).
Treatment study. We randomly separated 60 female adult rats into 6 groups and we injected the study drugs for 30 days: Control (1 mL/kg/day saline); L-NAME (20 mg/kg/day); L-NAME (20 mg/kg/day) + Depo (0.25 µg/kg once every 3 days); L-NAME (20 mg/kg/day) + Rem (5 mg/kg/day infliximab [Inf]; Janssen Biotech, Inc., Horsham, PA, USA); L-NAME (20 mg/kg/day) + Depo (0.25 µg/kg once every 3 days) + Rem (5 mg/kg/day); and Depo (0.25 µg/kg once every 3 days).

Ozkurt M., Uzuner K., Erkasap N., Kus G., Ozyurt R., Uysal O., Akyazi I, & Kutlay O. (2018). Erythropoietin Protects the Kidney by Regulating the Effect of TNF-α in L-NAME-Induced Hypertensive Rats. Kidney & blood pressure research, 43(3).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!